Blood clot risk study in CRPS patients
This study looks at factors that might increase the risk of blood clots in people with CRPS (Complex Regional Pain Syndrome). It aims to help doctors better understand and manage these risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with CRPS (Complex Regional Pain Syndrome) using the Budapest clinical criteria.
- You are able to give consent to participate.
- You are willing to have your blood clot risks assessed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an intravenous medicine called AMBTX-01 (neridronate) can help people with early-stage Complex Regional Pain Syndrome (CRPS) type 1. It focuses on those whose affected limb feels warm, looks red, and is swollen.
This study is testing a new way to measure CRPS symptoms and other chronic pain in one arm or leg. It aims to help doctors better understand and treat your condition.
This study looks at differences in gut bacteria (from a stool sample) in people with complex regional pain syndrome (CRPS) and in people who live with them. The goal is to understand whether gut microbes might play a role in CRPS and improve understanding of the condition.
This trial aims to learn more about blood clots, inflammation, and blood vessel problems. It may help researchers better understand these conditions and how they affect people.
This study uses ultrasound and a nerve test to evaluate the median nerve in people with CRPS type I (no known nerve injury). It aims to understand how ultrasound can help diagnose and monitor the condition.
This study looks at how signs in the body change over time in children with CRPS (complex regional pain syndrome). It mainly involves being assessed alongside the usual CRPS care, and often includes MRI checks to better understand the pain course.
Hear when a new Algoneurodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.